Galapagos is taking a leaf out of the Sanofi playbook for offloading unwanted French R&D units. Seeking to slim down to execute its new strategy, the Belgian biotech has struck a deal to transfer a facility on the outskirts of Paris to the drug discovery contract research organization (CRO) NovAliX.
The 6,753 square meter facility in Romainville, France is Galapagos’ second largest by headcount, trailing only its headquarters in Mechelen, Belgium. At the end of last year, the biotech employed 254 people at the French site, all of whom were represented by a labor union and/or covered by a collective bargaining agreement. The lease on the facility is set to expire in 2027.
Mass layoffs in France are covered by labor laws that complicate the process for companies. To bypass those complications, Sanofi has previously opted to offload rather than close facilities, handing sites to the CRO Evotec in 2015 and 2018. Now, Galapagos has gone down the same route.
“As a result of the acquisition, Galapagos’ employees in Romainville who are exclusively dedicated to the operation of these activities will be transferred to NovAliX who is dedicated to assuming all ongoing research and discovery activities in Romainville,” Galapagos wrote in a statement.
In return, Galapagos is “committed to utilizing the research capabilities and expertise of NovAliX through a five year-collaboration and within the context of the company’s R&D portfolio.” The Belgian biotech factored the financial impact of the deal into its previous 2023 cash burn forecast of up to €420 million ($457 million). Galapagos expects the transaction to close in July.
Paul Stoffels, M.D., who took over as CEO and chairman of Galapagos last year, framed the deal as part of the pivot in R&D strategy that he outlined late last year. At the time, Galapagos said it planned to reduce its headcount by approximately 200 positions across its sites in Europe.
By Nick Paul Taylor
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.